Use of aromatase inhibitors in breast carcinoma

Endocrine-Related Cancer

Volumn 6, Issue 1, 1999, Pages 75-92

  Santen, R J ^b   Harvey, H A ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450; ESTRADIOL; EXEMESTANE; FADROZOLE; FORMESTANE; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; VOROZOLE;

ABSCESS; BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME REGULATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; META ANALYSIS; PATIENT SELECTION; RASH; REVIEW; SOMNOLENCE; TREATMENT INDICATION;

ADULT; AMINOGLUTETHIMIDE; ANDROSTADIENES; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG DESIGN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; PREMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 0032892317     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060075     Document Type: Review

References (70)

1. Abul-Hajj, Iverson R & Kiang DT 1979 Aromatization of androgens by human breast cancer. Steroids 33 205-222.
2. Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Alemany F, Gomez-Batiste X, Fabregat-Mayol J & Viladiu-Quemada P 1988 Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced breast cancer. Oncology 45 350-353.
3. Bezwoda WR, Mansoor N & Dansey R 1987 Correlation of breast tumor aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 44 345-349.
4. Brodie AM 1993 Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacological Therapies 60 501-515.
5. Brodie A, Long B, Liu Y & Lu Q 1999 Aromatase inhibitors and their anti-tumor effects in model systems. Proceeding of the Conference 'Aromatase and its Inhibitors: New Biology and Perspectives', Prague, Czech Republic, 3-5 September 1998. Endocrine-Related Cancer 6 (In Press).
6. Brodie AM & Wing LY 1987 In vitro and in vivo studies with aromatase inhibitor 4-hydroxy-androstenedione. Steroids 50 89-103.
7. Brodie AMH, Romanoff ID & Williams KIH 1981 Metabolism of the aromatase inhibitor 4-hydroxy-4-androstenedione,3,17-dione by male rhesus monkeys. Journal of Steroid Biochemistry 14 693-696.
8. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eirmann W, Wolter JM, Azab M, Webster A & Plourde PV 1996a Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Journal of Clinical Oncology 14 2000-2011.
9. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M & Cooper J 1996b Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials. Cancer 71 2503-2513.
10. Buzdar A, Jonat W, Howell A, Yin H & Lee D 1997 Significant improved survival with Arimadex (anastrazole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proceedings of the American Society of Clinical Oncology 16 Abstract 545.
11. Buzdar AU 1998 Anastrozole: a new addition to the armamentarium against advanced breast cancer. American Journal of Clinical Oncology 21 161-166.
12. Cocconi G 1994 First generation aromatase inhibitors -aminoglutethimide and testololactone. Breast Cancer Research and Treatment 30 57-80.
13. Coombes RC, Wilkinson JR, Bliss JM, Shah P, Easton DF & Dowsett M. 1991 4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis. British Journal of Cancer 64 247-250.
14. Demers LM, Lipton A, Harvey HA, Kambic KB, Grossberg H, Brady C & Santen RJ 1993 The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. Journal of Steroid Biochemistry and Molecular Biology 44 647-649.
15. Dickson RB & Lippman ME 1995 Growth factors in breast cancer. Endocrine Reviews 16 559-589.
16. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffman W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U & Trumet PF 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
17. Dowsett M, Jeffcoate SL, Santner S, Santen RJ, Stuart-Harris & Smith IE 1985 Low dose aminoglutethimide and aromatase inhibition. Lancet i 175-176.
18. Dowsett M, Jones A, Johnston SRD 1995 In vivo measurement of aromatase inhibition by letrozole (20267) in post-menopausal patients with breast cancer. Clinical Cancer Research 1 1511-1515.
19. Evans TRJ, diSalle E, Ornati G et al. 1992 Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Research 52 5933-5939.
20. Falkson CI & Falkson HC 1996 A randomized study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Annals of Oncology 7 465-469.
21. Fishman J & Hahn EF 1987 The nature of the final oxidative step in the aromatization sequence. Steroids 50 339-345.
22. Frantz AG & Wilson JD 1998 Endocrine disorders of the breast. In Williams Textbook of Endocrinology, edn 9, pp 877-900. Philadelphia: WB Saunders Company.
23. Gale KE, Anderson JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ & Cummings FJ 1994 Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73 354-361.
24. Geisler J, Lien EA, Ekse D & Lonning PE 1997 Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrostenedione sulphate in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 63 53-58.
25. Gershanovich M, Chaudri H, Campos D Lurie H, Bonaventura A, Jeffrey M. Buzzi F, Bodrogi I, Ludwig H, REichardt P, O'Higgins N, Romieu G, Friederich P & Lassus M1998 Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology 9 639-645.
26. Goss P 1998 Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Breast Cancer Research and Treatment 49 S59-S65.
27. Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC & Coombes RC 1986 Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Research 46 4823-4826.
28. Gottardis MM & Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48 5183-5187.
29. Grodin JM, Siiteri PK & MacDonald PC 1973 Source of estrogen production in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 36 207-214.
30. Gunson DE, Steele RE & Chau RY 1995 Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. British Journal of Cancer 72 72-75.
31. Harada N, Honda S & Hatano O 1999 Aromatase inhibitors and enzyme stability. Proceedings of the Conference 'Aromatase and its Inhibitors: New Biology and Perspectives', Prague, Czech Republic, 3-5 September 1998. Endocrine-Related Cancer 6 (In Press).
32. Harvey HA 1996 Aromatase inhibitors in clinical practice; current status and a look to the future. Seminars in Oncology 23 33-38.
33. Harvey HA, Lipton A, Santen RJ, Demers L, Henderson IC, Garber JE, Miller AA, Navari R, Mulagha M & Hanagan J 1994 Phase I and phase II clinical trials of fadrozole hydrochloride in postmenopausal women with metastatic breast cancer. Advanced Clinical Oncology 2 155-158.
34. Hoffken K, Jonat W, Possinger K, Kolbel M, Kunz T, Wagner H, Becher R, Callies R, Friederich P & Willmanns W 1990 Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer. A phase II study. Journal of Clinical Oncology 8 875-880.
35. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J & Sellwood RA1998 The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. European Journal of Cancer and Clinical Oncology 24 1567-1572.
36. Iveson TJ, Smith IE, Ahern J et al. 1993 Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in post-menopausal patients with breast cancer. Cancer Research 53 266-270.
37. Jones AL, MacNeil F, Jacobs S, Lonning PE & Powles TJ 1992 The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. European Journal of Cancer 28A 1712-1716.
38. Kleeberg UR, Dowsett M, Carrion RP, Dodwell DJ, Vorobiof DA, Aparicio LA & Robertson JF 1997 A randomized comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. Oncology 54 (Suppl 2) 19-21.
39. Leltzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L & Lipton A1995 Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Clinical Oncology 13 1129-1135.
40. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G & Shafik A 1982 A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50 2265-2268.
41. Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, Adlercreutz, Trunet PF & Santen RJ 1995 Letrozole (CGS 20267) - phase I study of a new potent aromatase inhibitor in breast cancer. Cancer 75 2132-2138.
42. Lonning, PE 1998 Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment 49 S45-S52.
43. Lonning PE, Geisler J, Johannessen DC & Ekse D 1997 Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology 61 255-260.
44. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
45. Miller WR & O'Neil JS 1987 The importance of local synthesis of estrogen within the breast. Steroids 50 537-548.
46. Mor G, Yue W, Santen RJ, Gutierrez L, Eliza M, Berstein L, Harada N, Wang J, Lysiak J, Diano S & Naftolin F 1998 Macrophages, estrogen and the microenvironment of breast cancer. Journal of Steroid Biochemistry and Molecular Biology 67 403-414.
47. Oerter-Klein K, Demers LM, Santner SJ, Baron J, Cutler GB Jr & Santen RJ 1995 Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. Journal of Clinical Endocrinology and Metabolism 80 2658-2660.
48. Samojlik E, Santen RJ & Worgul TJ 1982 Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma. Steroids 39 497-507.
49. Santen RJ 1997 Long term tamoxifen therapy: can an antagonist become an agonist? (Editorial). Journal of Clinical Endocrinology and Metabolism 81 2027-2029.
50. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978 Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast cancer. Journal of Clinical Endocrinology and Metabolism 47 1257-1265.
51. Santen RJ, Samojlik E & Wells SA 1980 Resistance of the ovary to blockade of aromatization with aminoglutethimide. Journal of Clinical Endocrinology and Metabolism 51 473-477.
52. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C & Wells S 1981 A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. New England Journal of Medicine 305 545-551.
53. Santen RJ, Worgul TJ, Lipton A, Harvey HA, Boucher A, Samojlik E & Wells SA 1982 Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma: correlation of clinical and hormonal responses. Annals of Internal Medicine 96 94-101.
54. Santen RJ, Manni A, Harvey H & Redmond C 1990 Endocrine treatment of breast cancer in women. Endocrinology Reviews 11 221-265.
55. Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, Garber JE, Henderson IC, Navari RM & Miller AA 1991 Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. Journal of Clinical Endocrinology and Metabolism 73 99-106.
56. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, Hafer L, Zaino R & Santner SJ 1994 Stromal spindle cells contain aromatase in human breast tumors. Journal of Clinical Endocrinology Metabolism 79 627-632.
57. Santen, RJ, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G & Berstein L 1999 Potential role of aromatase overexpression in the genesis of breast carcinoma. (Monograph). Journal of the National Cancer Institute (In Press).
58. Sasano H & Harada N 1998 Intratumoral aromatase in human breast, endometrial and other malignancies. Endocrine Reviews 19 593-607.
59. Schiweck K, Bhatnagar AS, Batzl CH & Lang M 1993 Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. Journal of Steroid Biochemistry and Molecular Biology 44 633-636.
60. Simpson ER, Merrill JC, Hollub AJ, Graham-Lorence S & Mendelson CR 1989 Regulation of estrogen biosynthesis by human adipose cells. Endocrine Reviews 10 136-148.
61. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Corbin CJ & Mendelson CR 1993 Tissue specific promoters regulate aromatase cytochrome P450 expression. Clinical Chemistry 39 317-324.
62. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K & Mendelson CR 1997 Aromatase expression in health and disease. Recent Progress in Hormone Research 52 185-213.
63. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parsons CA, Villardo A, Walsh G & McKinna JA 1981 Tamoxifen versus aminoglutethimidein advanced breast carcinoma: a randomized cross-over trial. British Medical Journal 283 1432-1434.
64. Swain SM, Steinberg SM, Bagley C & Lippman ME 1988 Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer -a randomized study. Breast Cancer Research and Treatment 12 51-57.
65. Thurlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn HJ, Fey M & Lohnert T 1996 First line fadrozole HCL (CGS 16949A) versus tamoxifen in postmenopausal patients with advanced breast cancer. Annals of Oncology 7 471-496.
66. Thurlimann B, Paridaens R, Seroin D, Bonneterre J, Roche H, Murray R, diSalle E, Lanzalone S, Zurlo MG & Piscitelli G 1997 Third-line hormonal treatment with exemestane in post-menopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Examestane Study Group. European Journal of Cancer 33 1767-1773.
67. Trunet PF, Vreeland F, Royce C, Chaudri HA, Cooper J & Bhatnagar AS 1997 Clinical use of aromatase inhibitors in the treatment of advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology 61 241-245.
68. Yamaguchi study from Prague meeting. Endocrine Related Cancer (In Press) 1999.
69. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S & Hayes DF 1997 Prediction of response to anti-estrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. Clinical Oncology 15 2518-2525.
70. Yue W, Wang J-P, Hamilton CJ, Demers LM & Santen RJ 1998 In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Research 58 927-932.